Rajeswara Patcha, MD
Interventional Cardiology · Huntington, NYNPI 1104829407
Payments from drug & device makers
Across 265 payments — averaging $21.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$718
- Medtronic$694
- Abbott$674
- Novartis$516
- Amgen$367
- Pfizer$242
- plus $3K from 32 others
What the payments were for
- Food & beverage$5,766100%
- Education$190%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boston Scientific | 20 | $718 |
| Medtronic(2 entities) | 59 | $694 |
| Abbott | 18 | $674 |
| Novartis | 32 | $516 |
| Amgen | 19 | $367 |
| Pfizer | 13 | $242 |
| Amarin Pharma, Inc. | 10 | $207 |
| Astellas Pharma US Inc | 8 | $174 |
| Edwards Lifesciences | 3 | $168 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 8 | $144 |
| Boehringer Ingelheim | 6 | $134 |
| Sanofi-aventis U.S. LLC | 6 | $130 |
| Shockwave Medical, Inc | 2 | $125 |
| Atricure, Inc. | 3 | $117 |
| Biotronik Inc. | 2 | $115 |
| E.r. Squibb & Sons, L.L.C. | 6 | $113 |
| Masimo Corporation | 1 | $107 |
| Abiomed | 1 | $98 |
| Esperion Therapeutics, Inc. | 4 | $84 |
| Merck | 4 | $82 |
| Johnson & Johnson | 5 | $81 |
| Philips North America LLC | 3 | $77 |
| Kowa Pharmaceuticals America, Inc. | 6 | $77 |
| Kiniksa Pharmaceuticals International, PLC | 3 | $75 |
| Tactile Systems Technology Inc | 3 | $73 |
| Bardy Diagnostics, Inc. | 3 | $57 |
| AstraZeneca | 3 | $51 |
| Irhythm Technologies, Inc. | 2 | $44 |
| Novo Nordisk | 2 | $42 |
| Angiodynamics, Inc. | 2 | $40 |
| Baxter Healthcare | 1 | $29 |
| Intra-sana Laboratories | 1 | $25 |
| Braemar Manufacturing, LLC | 1 | $24 |
| Regeneron Healthcare Solutions, Inc. | 1 | $22 |
| Bayer | 1 | $20 |
| Heartflow, Inc. | 1 | $14 |
| Cardiovascular Systems Inc. | 1 | $13 |
| Penumbra, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,785 in reported general payments places this provider in the 35th percentile of 382 interventional cardiology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 370 | $458,164 |
| XareltoRivaroxaban | 78 | $91,401 |
| Repatha SureclickEvolocumab | 69 | $77,921 |
| EntrestoSacubitril/Valsartan | 27 | $36,838 |
| FarxigaDapagliflozin Propanediol | 22 | $30,128 |
| MounjaroTirzepatide | 20 | $19,999 |
| OzempicSemaglutide | 18 | $18,052 |
| MultaqDronedarone Hcl | 11 | $17,402 |
| WegovySemaglutide | 11 | $14,477 |
| Praluent PenAlirocumab | 12 | $11,924 |
| Metoprolol Succinate | 494 | $9,436 |
| Rosuvastatin Calcium | 291 | $4,063 |
| ClopidogrelClopidogrel Bisulfate | 318 | $3,702 |
| Candesartan Cilexetil | 30 | $3,514 |
| Losartan Potassium | 203 | $2,224 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $242 | $458,164370 claims |
| Johnson & JohnsonXarelto | $81 | $91,40178 claims |
| NovartisEntresto | $516 | $36,83827 claims |
| Novo NordiskOzempic, Wegovy | $42 | $32,52929 claims |
| AstraZenecaFarxiga | $51 | $30,12822 claims |
| Sanofi-aventis U.S. LLCMultaq | $130 | $17,40211 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 382 interventional cardiology providers in New York.
Other interventional cardiology in Huntington
- Martin LeonNew York$13.5M
- David CohenRoslyn$9.8M
- Susheel KodaliNew York$6M
- Mohamed Azeem LatibBronx$4.6M
- Richard ShlofmitzRoslyn$4.5M
- Deepak BhattNew York$4.1M
- Samin SharmaNew York$3.7M
- Annapoorna KiniNew York$3.5M
- Sahil ParikhNew York$2.7M
- George DangasNew York$2.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.